BioSpace News Archive

HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO’s HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab), a PD-1 blocking antibody

Proceeds will support development of novel myeloid checkpoint inhibitors including its clinical program IO-202, a first-in-class LILRB4 antagonist antibody in blood cancers and solid tumors, and its preclinical programs IO-108 and IO-106, targeting LILRB2 and LAIR1 respectively

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a webcast to review the preclinical data being presented from its CDC7 program during a virtual poster session at the upcoming American Association for Cancer Research (AACR) Annual Meeting.

Proscia®, a leading provider of digital and computational pathology solutions, and Unilabs, a leading international provider of diagnostic services, have established a strategic partnership to accelerate the adoption of artificial intelligence (AI) in routine pathology practice

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today announced the appointment of Dennis Giesing, Ph.D., to the role of Chief Development Officer (CDO). In this position,

Exelixis, Inc. (Nasdaq: EXEL) today announced that COSMIC-313, the phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX ® ), nivolumab (OPDIVO ® ) and ipilimumab (YERVOY ® ) versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma (RCC), has completed enrollment.

Aphios Corporation announced today that it has been granted United States Patent No. 10,954,248 entitled “Bryoid Compositions, Methods of Making and Use Thereof.” This patent is part of a family of Aphios patents in Europe (Patent No. 2,925,315, Jan. 16, 2019), Japan (Patent No. 6,440,628, Nov. 30, 2018), Hong Kong (Patent No. HK1,216,891, Nov. 22, 2019), and China (Patent No. ZL201380069328.2, Oct. 19, 2018).

Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360 ® CDx Test

Inversago Pharma Inc., the peripheral CB1 blockade company, today announced that François Ravenelle, PhD, CEO and Founder, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference.

Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation.